Sanofi to acquire Vigil Neuroscience, Inc. for $470M
New England Council member, Sanofi, recently announced that it will acquire Vigil Neuroscience, Inc. and its treatment for Alzheimer’s disease. The deal is valued at around $470 million.
Sanofi has stated that the acquisition will enable the company to expand its early-stage pipeline in neurology, one of Sanofi’s four strategic disease areas. Vigil’s Alzheimer’s drug, VG-3927, will be evaluated in phase 2 of the clinical study. The therapy utilizes an oral small-molecule TREM2 agonist, which, when activated, is expected to enhance the neuroprotective function of microglia in Alzheimer’s disease.
“This acquisition is fully supporting Sanofi’s strategic focus on neurology and on advancing science and leveraging our expertise in immunology to solve areas of critical unmet need … Vigil’s expertise is complementary to our capabilities in neurology and reinforces our dedication to developing innovative medicines to improve people’s lives. Vigil’s team are a welcome addition, and we look forward to working with them and the patient community” said Houman Ashrafian, Sanofi’s Head of Research and Development.
The New England Council congratulates Sanofi on this acquisition, which will expand its neurology pipeline.
Read more in Sanofi’s press release and the Boston Business Journal.